The Recession And Its Impact On Pharamceutical M&a Activity
The Recession and its impact on Pharamceutical M&A Activity
Expert analysis and detailed case histories illuminate the effect on, and activities of, pharmaceutical companies in the current economic downturn.
Mergers and, more commonly, acquisitions have long been popular in the pharmaceutical industry. Whether it has been to support flagging drug pipelines, secure IP on promising drug candidates or to quickly access new markets, the industry has for many years been characterised by a vibrant M&A culture. The current recession has, therefore, had a significant impact on the industrys players, and in more ways than might be immediately obvious.
The limited availability of credit to fund through share issue or capital loans drug discovery programmes, has denied many development companies the ability to progress independently. At the other end of the scale, high-profile acquisitions have had to be funded from cash. The ability of companies to operate on this basis has been limited by the level of liquidity they hold and an increased awareness of the short-term benefits of revenue increase and cost savings.
Activity expands
The nature of the recession and the limited access to credit has sparked a round of mergers and acquisitions. Companies unable to secure the finance they need have been opportunistically targeted by those with the means to buy.
Key Chapters :
INTRODUCTION - THE RECESSION DEFINED
PART 1 - THE RECESSION TRACED
- Roots
-- Figure 1: US Consumer Debt Jan. 2001 - April 2009
-- Figure 2: Quarterly US Consumer Debt Ratio 2001 - 2008
- Problems in the Financial Markets
-- Figure 3: European Interbank Lending Rates (EURIBOR)
- How to Stem the Tide
-- Figure 4: Average Interest Rates charged on short terms loans to business
-- Figure 5: Euro and US Monthly Commercial Paper Rates 2003 - 2009
-- Figure 5: US Manufacturing Index February 2001 - May 2009
- The Real Economy
-- Figure 6: US Manufacturing Index January 1972 - May 2009
-- Figure 7: Month on Month % Change in US Manufacturing, January 1972 - May 2009
PART 2 - IMMUNITY DECLINED
- Immunity Explained
- Development-Stage Companies
- CV Therapeutics
-- Table 1: CV Therapeutics' Accounts
-- Figure 8: CV Therapeutics Cash Flows
- Amylin Pharmaceuticals
-- Table 2: Amylin Pharmaceuticals Accounts
-- Figure 9: Amylin Pharmaceuticals Cash Flows
-- The Ability to Manufacture and Positive Cash Flow
-- Table 3: CV Therapeutics Underlying Loss and Finance Income 2000 - 2008 (US$ million)
-- Figure 10: CV Therapeutics Underlying Loss and Finance Income 2000 - 2008
- Generics
-- Figure 11: Diflucan Annual Sales
-- Figure 12: Lipitor Annual Sales
-- Figure 13: Lipitor Cumulative Revenues from 1999
-- Figure 14: US Pharmaceutical and Medicines Index
To know more and to buy a copy of your report feel free to visit :
http://www.bharatbook.com/detail.asp?id=160107&rt=The-Recession-and-its-impact-on-Pharamceutical-M-A-Activity.html
Or
Contact us at :
Bharat Book Bureau
Tel: +91 22 27578668
Fax: +91 22 27579131
Email: info@bharatbook.com
Website: www.bharatbook.com
Follow us on twitter: http://twitter.com/3bbharatbook
by: Bharat Book Bureau
Fashion & Design Academy Are You Concerned About Your Online Reputation Local Philippines: Better Leyte Than Never by:Allan Leandro Merina Why Prepare Systematically To Deliver A Few Checks? (chapel 2) My Wife Wants a Divorce - Here's How to Change Her Mind and Win Her Back Are There Risks When Investing In Penny Stocks? Corporate Removals to Ireland Presto 23 Quart Pressure Canner Review - A Useful and Versatile Cooking Piece Choosing wedding dress Ranch Holiday The Dangers Of Selling Kids' Information Online Best Parenting Books To Give You A Hand In Raising Your Young Katrina Kaif is Sexiest Asian Woman in the World